PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in H. pylori persistence, PCN subgroup compared with 7 days (low certainty).
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PAN subgroup compared with 7 days (moderate certainty).
PPI triple therapy for 14 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PCN subgroup compared with 7 days (very low certainty).
It is very uncertain whether the intervention changes perioperative mortality (very low certainty).
It is very uncertain whether the intervention changes treatment withdrawal (very low certainty).
It is very uncertain whether the intervention changes re‐operation (very low certainty).
The intervention showed no clear difference in anastomotic leak; GRADE not reported.
It is very uncertain whether the intervention changes pancreatic fistula (clinically significant) (very low certainty).
The intervention showed no clear difference in infected abdominal collections; GRADE not reported.
The intervention showed no clear difference in shock; GRADE not reported.
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
The intervention probably leads to lower lymph node mets analysis ‐ N+ OS (moderate certainty).
Post‐surgical chemotherapy leads to lower disease Free Survival compared with surgery alone (high certainty).
The intervention probably leads to lower chemobased OS ‐ 5‐FU based chemotherapy OS (moderate certainty).
The intervention showed no clear difference in chemobased OS ‐ Platinum‐based chemotherapy OS (moderate certainty).